SCHEMBL2439211

SCHEMBL2439211

NC(=O)c1cc(Oc2ccc3c(C(=O)Nc4cccc(C(F)(F)F)c4)cccc3c2)ccn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.72
FLT1 P17948 4/20 0.72
FLT4 P35916 4/20 0.72
RET P07949 3/20 0.72
PDGFRB P09619 2/20 0.72
KIT P10721 2/20 0.72
PLK4 O00444 1/20 0.57
AURKA O14965 1/20 0.57
MAPK13 O15264 1/20 0.57
JAK2 O60674 1/20 0.57
MAP4K4 O95819 1/20 0.57
ABL1 P00519 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
LYN P07948 1/20 0.57
ROS1 P08922 1/20 0.57
SRC P12931 1/20 0.57
RPS6KB1 P23443 1/20 0.57
EPHA2 P29317 1/20 0.57
TYK2 P29597 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435904 0.92 KDR (0.70) KDRFLT1FLT4RETPDGFRB
SCHEMBL2437469 0.90 KDR (0.71) KDRFLT1FLT4RETPDGFRB
SCHEMBL2434221 0.89 KDR (0.77) KDRFLT1FLT4RETPDGFRB
SCHEMBL2748558 0.88 KDR (0.56) KDRFLT1FLT4RETPDGFRB
SCHEMBL2434509 0.88 KDR (0.81) KDRFLT1FLT4RETPDGFRB
SCHEMBL2435692 0.87 KDR (0.71) KDRFLT1FLT4RETPDGFRB
SCHEMBL4548907 0.86 KDR (0.62) KDRFLT1FLT4RETPDGFRB
SCHEMBL4548903 0.86 KDR (0.68) KDRFLT1FLT4RETPDGFRB
SCHEMBL2433816 0.86 KDR (0.69) KDRFLT1FLT4RETPDGFRB
SCHEMBL4548906 0.85 KDR (0.63) KDRFLT1FLT4RETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 US claimed
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor NOVARTIS AG (CH) 2012-07-05 US disclosed
EP-1945217-B1 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2012-05-02 EP disclosed
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 US disclosed
US-8026247-B2 Bicyclic amides as kinase inhibitors NOVARTIS AG (CH) 2011-09-27 US disclosed
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor NOVARTIS AG 2008-12-11 US disclosed
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors NOVARTIS AG (CH) 2008-11-20 US disclosed
EP-1794149-A2 BICYCLIC AMIDES AS KINASE INHIBITORS Novartis AG (CH) 2007-06-13 EP disclosed
WO-2006059234-A2 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor KDR, FLT4, FLT1 KDR 1/4885FLT1 3/4885FLT4 2/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 KDR 826/4885FLT1 638/4885FLT4 944/4885
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors MAP3K20, MAP3K1, MAP3K19 KDR 888/4885FLT1 678/4885FLT4 992/4885
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor KDR, FLT4, FLT1 KDR 1/4885FLT1 3/4885FLT4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.